CVS Health Corp. (NYSE:CVS)

The period under review demonstrates fluctuating financial performance as measured by economic profit. Net operating profit after taxes (NOPAT) exhibited volatility, beginning at US$9,067 million, decreasing significantly to US$3,871 million, then recovering to US$9,523 million before declining again to US$5,319 million. The cost of capital generally increased from 7.62% to 8.95% before decreasing to 8.01%. Invested capital showed a decreasing trend initially, followed by an increase, and then a slight decrease.

Economic Profit Trend

Economic profit consistently remained negative throughout the observed period. The largest negative economic profit occurred in 2022, reaching -US$7,203 million. While the negative economic profit lessened in 2021 to -US$2,374 million, it worsened considerably in 2022. A reduction in the magnitude of the loss was observed in 2023 (-US$1,698 million), but the economic profit again became more negative in 2024 (-US$5,219 million).

Relationship between NOPAT and Economic Profit

The fluctuations in NOPAT appear to strongly correlate with the changes in economic profit. The substantial decline in NOPAT in 2022 directly contributed to the most significant negative economic profit for that year. The recovery in NOPAT in 2023 resulted in a less negative economic profit, indicating that improvements in operational profitability can mitigate the negative impact of the cost of capital. However, the subsequent decline in NOPAT in 2024 led to a larger negative economic profit.

Impact of Cost of Capital

The cost of capital increased between 2020 and 2022, potentially exacerbating the negative economic profit during that period. The subsequent decrease in the cost of capital in 2023 and 2024 may have partially offset the negative impact of lower NOPAT in 2024, but was not sufficient to generate a positive economic profit.

Invested Capital Considerations

While invested capital decreased initially, the increase in 2023 suggests potential investments or changes in asset allocation. However, the level of invested capital did not appear to directly correlate with the economic profit performance, as the largest negative economic profit occurred with a relatively lower level of invested capital in 2022.

Overall, the analysis indicates that the entity consistently failed to generate returns exceeding its cost of capital during the examined timeframe. The negative economic profit trend suggests a need for strategies to improve operational profitability, manage the cost of capital, or optimize capital allocation.

Net income attributable to CVS Health

The net income exhibited fluctuations over the five-year period. Starting at $7,179 million in 2020, there was an increase to $7,910 million in 2021, indicating growth. However, in 2022, net income notably declined to $4,149 million, reflecting a significant drop. This was followed by a rebound in 2023, reaching $8,344 million, which represents the highest point in the period. In 2024, net income once again decreased to $4,614 million, showing volatility and an overall irregular pattern in earnings.

Net operating profit after taxes (NOPAT)

NOPAT followed a pattern broadly similar to net income but with less pronounced volatility. It began at $9,067 million in 2020 and slightly increased to $9,170 million in 2021. In 2022, there was a sharp decline to $3,871 million, mirroring the net income decline of that year. The subsequent year, 2023, saw a recovery to $9,523 million, the highest level observed in this timeframe. By 2024, NOPAT decreased again to $5,319 million. This trend suggests that while operating profitability is subject to cyclical pressures, it remains relatively strong when it rebounds.

Insights

The data reveals substantial volatility in both net income and NOPAT with synchronous fluctuations particularly pronounced in 2022 and 2024. These troughs could indicate periods of operational or market challenges impacting profitability. Despite these downturns, the company demonstrated resilience with robust recoveries in 2023, suggesting effective management responses or favorable market conditions during that year. The gap between net income and NOPAT levels also suggests that non-operating factors or tax impacts may play a role in overall profitability fluctuations. The irregular pattern underscores the importance of closely monitoring operational efficiency and external factors influencing financial performance.

Income Tax Provision

The income tax provision exhibited a fluctuating trend over the years observed. It decreased from $2,569 million in 2020 to $2,522 million in 2021, indicating a slight reduction. This was followed by a more significant decline to $1,463 million in 2022. However, in 2023, the provision increased sharply to $2,805 million, before decreasing again to $1,562 million in 2024. Overall, the income tax provision shows variability with notable peaks and troughs during the five-year period.

Cash Operating Taxes

Cash operating taxes showed a moderate decline from $3,769 million in 2020 to $3,407 million in 2021. In 2022, there was an increase to $4,013 million, marking the highest point in the period reviewed. Subsequently, the amount slightly decreased to $3,965 million in 2023, followed by a significant drop to $2,464 million in 2024. This pattern indicates some volatility with an overall downward movement towards the end of the period.

Comparative Insights

Both income tax provision and cash operating taxes demonstrate considerable year-to-year fluctuations. Cash operating taxes consistently remained higher than the income tax provision across all years. The disparity between the two measures also varied, with the smallest gap occurring in 2024. This suggests possible changes in tax planning, timing differences, or cash tax payments relative to accounting tax expense over the evaluated periods.

Total reported debt & leases

The total reported debt and leases decreased from 85,042 million US dollars at the end of 2020 to 70,732 million US dollars by the end of 2022. This decline indicates a reduction in leverage during this period. However, starting from 2023, there is a notable increase, rising to 79,385 million US dollars and further to 82,920 million US dollars by the end of 2024, suggesting renewed borrowing or leasing commitments.

Total CVS Health shareholders’ equity

Shareholders’ equity showed a rising trend from 69,389 million US dollars in 2020, peaking at 75,075 million in 2021. Following this peak, equity experienced a slight pullback to 71,015 million in 2022 but recovered to 76,461 million in 2023. By 2024, it marginally declined again to 75,560 million US dollars. Overall, equity levels remained relatively stable with moderate fluctuations around the mid-70 billion range in the most recent years.

Invested capital

Invested capital declined steadily from 136,669 million US dollars in 2020 to 123,703 million in 2022, reflecting overall reductions in capital employed. This trend reversed in 2023 with an increase to 134,694 million followed by a slight decrease to 131,642 million in 2024. The pattern suggests a cycle of divestments or asset optimization up to 2022 and subsequent reinvestment or capital expansion over the following years, indicating adjustments in capital structure or operational focus.

The economic spread ratio exhibited considerable fluctuation between 2020 and 2024. Initially negative, the ratio demonstrated a significant decline through 2022 before partially recovering in subsequent years. Economic profit consistently remained negative throughout the analyzed period, though with varying magnitudes.

Economic Spread Ratio

In 2020, the economic spread ratio was -0.99%. This indicates that the company’s return on invested capital was less than its cost of capital. The ratio worsened substantially in 2021, reaching -1.81%, and continued to deteriorate to -5.82% in 2022, representing the lowest point in the observed period. A notable improvement occurred in 2023, with the ratio increasing to -1.26%. This positive shift suggests a narrowing gap between returns and capital costs. However, the ratio decreased again in 2024 to -3.96%, indicating a renewed widening of this gap.

Economic Profit

Economic profit began at -1,348 million in 2020 and decreased to -2,374 million in 2021. The largest absolute value of economic loss occurred in 2022, at -7,203 million. A substantial increase in economic profit was observed in 2023, moving to -1,698 million, suggesting improved performance relative to capital employed. In 2024, economic profit decreased to -5,219 million, representing a return to a higher level of economic loss compared to 2023, but still less severe than the loss experienced in 2022.

Invested Capital

Invested capital decreased from 136,669 million in 2020 to 130,882 million in 2021, and further to 123,703 million in 2022. A subsequent increase was noted in 2023, reaching 134,694 million. In 2024, invested capital slightly decreased to 131,642 million. The fluctuations in invested capital may contribute to the observed changes in the economic spread ratio, although the primary driver appears to be the performance reflected in economic profit.

The interplay between economic profit and invested capital demonstrates a complex relationship. While invested capital fluctuated, the consistent negative economic profit suggests an ongoing challenge in generating returns exceeding the cost of capital. The improvement observed in 2023 was short-lived, as indicated by the 2024 figures.

The economic profit margin exhibited considerable fluctuation between 2020 and 2024. Initially negative, the margin worsened significantly over the period before showing some improvement, though remaining negative overall. A review of the underlying figures reveals a complex relationship between revenue growth and economic profit generation.

Economic Profit Margin Trend

In 2020, the economic profit margin stood at -0.50%. This margin deteriorated substantially to -0.82% in 2021, and then experienced a marked decline to -2.24% in 2022. A significant positive shift occurred in 2023, with the margin improving to -0.48%. However, this improvement was not sustained, as the margin decreased again to -1.41% in 2024.

Relationship to Revenues

Revenues from customers demonstrated consistent growth throughout the five-year period, increasing from US$267,908 million in 2020 to US$370,656 million in 2024. Despite this revenue growth, economic profit remained negative each year. The most substantial revenue increase occurred between 2022 and 2023 (US$321,629 million to US$356,623 million), coinciding with the largest single-year improvement in the economic profit margin. However, the continued revenue growth in 2024 did not translate into a further improvement in economic profit margin.

Economic Profit

The absolute value of economic profit increased from US$-1,348 million in 2020 to US$-2,374 million in 2021, then experienced a dramatic increase to US$-7,203 million in 2022. This was followed by a substantial reduction in the absolute loss to US$-1,698 million in 2023. The economic profit then increased in absolute value to US$-5,219 million in 2024, indicating a return to a more substantial economic loss despite continued revenue expansion.

The divergence between revenue growth and economic profit suggests that increases in operating costs, capital charges, or a combination of both, are outpacing revenue gains. Further investigation into the components of economic profit is warranted to understand the drivers behind this trend.